Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Immuron Limited - American Depositary Shares (OQ:IMRN)

Business Focus: N/A

Mar 07, 2024 06:00 am ET
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the interim topline results confirming that a single daily dose of Travelan® is effective in prevention of...
Feb 21, 2024 06:00 am ET
Immuron Presentation Australian Biologics Festival 2024
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Festival 2024...
Feb 13, 2024 06:00 am ET
Immuron achieves record Travelan® sales
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited net sales) of Travelan®, an over-the-counter immune supplement that targets pathogenic...
Feb 08, 2024 06:00 am ET
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Monsoon Communications Investor function on...
Jan 16, 2024 06:00 am ET
Immuron achieves record half yearly Travelan® sales
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record half yearly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health...
Dec 22, 2023 06:00 am ET
Immuron Clinical Trials Update
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to provide shareholders and the market with an update on the company’s clinical development portfolio. The NMRC has...
Dec 04, 2023 06:00 am ET
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that the US Naval Medical Research Command (NMRC) has initiated the clinical evaluation of a new oral therapeutic...
Nov 28, 2023 06:33 am ET
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar “Coffee Microcaps Morning Meeting”, to be held on Thursday, 30th of...
Nov 13, 2023 06:00 pm ET
Immuron CEO Steven Lydeamore Investor Webinar Presentation
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar on The Watchlist, to be held on Tuesday, 14th November, 2023, 1:00pm...
Oct 30, 2023 07:21 am ET
Immuron CEO Steven Lydeamore presented at AusBioInvest
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer, Steven Lydeamore, presented at AusBioInvest 2023 on Monday, October 30th in the...
Oct 18, 2023 06:00 am ET
Immuron Announces Travelan® Clinical Study Cohort 2 commences
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the second cohort of 34 participants have commenced the clinical trial to evaluate the efficacy of Travelan® to...
Oct 11, 2023 06:00 am ET
Immuron achieves record quarterly Travelan® sales
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record quarterly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune...
Sep 18, 2023 07:30 am ET
Immuron Limited Announces Participation in the LD Micro Main Event XVI
Presentation on Wednesday, October 4th at 11:00 PT
Sep 13, 2023 06:00 am ET
Immuron achieves record monthly Travelan® sales
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record monthly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune...
Sep 11, 2023 06:00 am ET
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the H.C. Wainwright 25th Annual...
Aug 14, 2023 06:00 am ET
Immuron to present at the Military Health System Research Symposium
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it will be presenting at The Military Health System Research Symposium (MHSRS), in Kissimmee, Florida from...
Jul 25, 2023 06:00 am ET
Immuron Announces First Patients Enrolled in Travelan® Clinical Study
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the first cohort of 30 participants have been enrolled into the clinical trial to evaluate the efficacy of...
Jul 24, 2023 06:00 am ET
Immuron CEO, Steven Lydeamore to present at Bioshares
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the 17th Bioshares Biotech Summit in Hobart,...
Jul 11, 2023 06:00 am ET
Immuron Business Update - Ateria Health launches Juvia™ in Australia
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to...
Jul 05, 2023 06:00 am ET
Immuron FY23 Sales increase 136% on FY22 Sales
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce FY23 sales (unaudited net sales) results of its over-the-counter gastrointestinal and digestive health immune...
Jun 30, 2023 06:00 am ET
Immuron Chairman Transition
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the transition of Paul Brennan from Non-Executive Director to Chairman, effective July 1, 2023. Dr Roger Aston...
Jun 22, 2023 06:00 am ET
Immuron Business Update: Letter to Shareholders
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to...
May 30, 2023 06:00 am ET
Immuron Initiates Recruitment of Travelan® Clinical Study
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it has received approval from the U.S. Army Medical Research and Development Command (USAMRDC) Office of...
May 16, 2023 07:30 am ET
Immuron Limited Announces Participation in the LD Micro Invitational XIII
Melbourne, Australia--(Newsfile Corp. - May 16, 2023) - Immuron Limited (ASX: IMC) (NASDAQ: IMRN) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private 1:1 meetings.
May 08, 2023 06:00 am ET
Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to...
May 02, 2023 06:00 am ET
Immuron CEO, Steven Lydeamore to present at Coffee Microcaps
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to...
Apr 19, 2023 06:00 am ET
Immuron Q3 FY23 Business Update Presentation
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to...
Apr 11, 2023 06:00 am ET
Q3 FY23 Business Update Webinar Notification
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to...
Apr 06, 2023 06:00 am ET
Immuron Q3 Sales reach 150% of 1H Sales
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to...
Feb 15, 2023 06:00 am ET
Immuron CEO, Steven Lydeamore to host an investor webinar
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, invites...
Jan 25, 2023 06:00 am ET
Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, today...
Jan 18, 2023 05:00 am ET
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to...
Jan 17, 2023 07:10 am ET
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to...
Dec 23, 2022 06:00 am ET
Immuron Receives FDA Approval for Travelan IND Application
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to...
Dec 05, 2022 06:00 am ET
Immuron Submits IND Application To FDA for Travelan
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to...
Nov 16, 2022 07:00 am ET
Immuron completes strategic investment in leading gut health biotech Ateria Health
Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it completed a strategic investment in Ateria Health Limited, a U.K. based company that has developed ground-breaking product for the treatment of irritable bowel syndrome (IBS),...
Oct 26, 2022 06:00 am ET
Immuron CEO, Steven Lydeamore to present at AusBioInvest
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases; is pleased to...
Oct 13, 2022 06:00 am ET
Immuron strategic investment in leading gut health biotech Ateria Health
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to...
Oct 04, 2022 06:00 am ET
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to...
Aug 29, 2022 07:00 am ET
Immuron CEO, Steven Lydeamore, to host an investor webinar
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; invites investors to join a live webcast hosted by...
Aug 19, 2022 06:00 am ET
Immuron Update on IMM-124E SARS-CoV-2 Research
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; today announced that it has deprioritized SARS-CoV-2...
Jul 26, 2022 06:00 am ET
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today announced that the US Naval Medical...
Jul 11, 2022 06:00 am ET
Immuron North American Travelan® Sales up 494% and Global sales up 431%
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to...
Jul 07, 2022 06:00 am ET
Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that it has...
May 11, 2022 06:00 am ET
Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today is pleased to announce that the US...
May 09, 2022 06:00 am ET
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today is pleased to provide shareholders...
May 05, 2022 08:22 pm ET
Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment...
Apr 27, 2022 06:00 am ET
Immuron Travelan® Global sales up 216%
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced the sales results of its commercially...
Apr 19, 2022 07:33 am ET
Immuron new MTEC project proposal “Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease”
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to advise that a new request...
Mar 16, 2022 09:30 am ET
Appointment of Paul Brennan as Non-Executive Director
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment...
Jan 17, 2022 06:00 am ET
Immuron Receives AUD $306,154 R&D Tax Concession Refund
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that under the...
Jan 13, 2022 06:00 am ET
Immuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that it has been...
Jan 12, 2022 06:00 am ET
Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the funding of a...
Nov 15, 2021 06:00 am ET
US DoD Uniformed Services University Travelers’ Diarrhea Clinical Update
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today is pleased to provide shareholders...
Nov 10, 2021 06:00 am ET
US DoD Naval Medical Research Center Clinical Update
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today is pleased to provide shareholders...
Oct 08, 2021 06:00 am ET
IMM-124E – Demonstrates Antiviral T-Cell Immunity
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, is pleased to notify shareholders of a...
Sep 23, 2021 11:00 pm ET
Immuron Director resignation
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today received the resignation of Mr...
Sep 23, 2021 09:00 am ET
Immuron planned Acquisition of R&D Vaccine Company
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today would like to provide shareholders...
May 13, 2021 06:00 am ET
IMM124E – May offer a New modality for Inhibition of SARS-CoV-2
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today is pleased to provide shareholders...
Jan 11, 2021 06:00 am ET
Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to announce that Chief Executive...
Dec 15, 2020 06:00 am ET
Immuron SARS-CoV-2 Research Agreement with Monash University
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to provide shareholders and the...
Nov 24, 2020 06:00 am ET
Immuron Receives AUD $358,280 R&D Tax Concession Refund
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is pleased to announce that under the Australian...
Nov 11, 2020 06:00 am ET
US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to announce that the...
Oct 12, 2020 06:00 am ET
Immuron Travelers’ Diarrhea Market Update
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to provide shareholders...
Jul 23, 2020 12:45 pm ET
Immuron Limited Announces Closing of $20.0 Million Registered Direct Offering
Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today announced the...
Jul 21, 2020 08:45 am ET
Immuron Announces $20.0 Million Registered Direct Offering
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today announced that it has entered into...
Jul 21, 2020 07:00 am ET
Immuron Reports Neutralizing Activity Against SARS-CoV-2 Key Points
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to announce that...
Jul 20, 2020 06:00 am ET
US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to announce that the...
Jun 19, 2020 06:00 am ET
Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to provide shareholders...
Jun 09, 2020 06:00 am ET
US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to provide shareholders...
Apr 28, 2020 06:00 am ET
Immuron Board Relinquish Cash Payment of Fees
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced that the cash payments of Board fees...
Apr 20, 2020 06:00 am ET
Immuron North American Travelan® Sales Up 95%, Global Sales Up 60%
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced the sales results of its commercially...
Mar 25, 2020 06:00 am ET
Resignation of CEO & Director and cost cutting amidst COVID-19
The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the Company. The World is in the midst of an unprecedented health crisis as a result of the COVID-19 pandemic....
Mar 03, 2020 07:00 am ET
Immuron Provides Update on First Half of FY20 Results
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced an update of its results for the first...
Feb 03, 2020 07:30 am ET
Immuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, announced that its commercially available and...
Jan 28, 2020 08:30 am ET
North American Travelan® sales up 98% in the first half of FY20
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced the sales results of its commercially...
Jan 08, 2020 08:00 am ET
Immuron CEO Dr. Gary S. Jacob to Present at Biotech Showcase Conference on January 13, 2020
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced that CEO Dr. Gary S. Jacob will...
Nov 21, 2019 07:00 am ET
Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced that the company recently...
Nov 04, 2019 11:30 am ET
Immuron Receives AUD $0.53M R&D Tax Concession Refund
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that under the...
Oct 14, 2019 07:30 am ET
Immuron North American Q1 Sales Up 111% YoY
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut-mediated pathogens, is pleased to announce sales results for...
Oct 02, 2019 09:31 am ET
Thinking about buying stock in Aurora Cannabis, TD Ameritrade, Canopy Growth Corp, Immuron, or Stars Group?
NEW YORK, Oct. 2, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AMTD, CGC, IMRN, and TSG.
Oct 02, 2019 09:00 am ET
New U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluate a New Therapeutic against Campylobacter
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the funding of a...
Sep 04, 2019 06:00 am ET
U.S. Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of travelers’ diarrhea
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today announced positive results from a...
Aug 16, 2019 06:00 am ET
Immuron to Commence Non-Deal Investor Roadshow
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today is pleased to release to shareholders and...
Aug 12, 2019 06:30 am ET
BriaCell Appoints Richard J. Berman to Board of Directors
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that it has appointed Mr. Richard J....
Aug 08, 2019 12:00 pm ET
Immuron Reports Results in Severe Alcoholic Hepatitis Clinical Trial
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced the topline results of the clinical...
Jul 17, 2019 06:00 am ET
Immuron Prices Underwritten Public Offering of ADSs
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced the pricing of an underwritten...
Jul 17, 2019 06:00 am ET
Immuron to Host Investor Webinar on July 18 to Provide Update on Recent Developments
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced today that it will participate in an investor webinar and Q&A session on Thursday, July 18, 2019, at 10:30 a.m. EST (US time), hosted by RedChip Companies....
Jul 16, 2019 04:31 pm ET
Immuron Announces Proposed Public Offering of ADSs
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced that it intends to offer and...
Jul 16, 2019 09:31 am ET
Thinking about buying stock in Bio-Path, Beyond Meat, Goldman Sachs, Immuron, or Zoom Communications?
NEW YORK, July 16, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BPTH, BYND, GS, IMRN, and ZM.
Jul 16, 2019 06:00 am ET
Immuron North American revenue surges by 52% in FY19
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced sales results for the year ended 30 June...
Jun 25, 2019 06:00 am ET
Immuron Directors Increase Shareholdings in the Company
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company wishes to advise that two of its Directors, Mr Peter Anastasiou and Mr Daniel Pollock have recently acquired on-market 1,000,000 (25,000 ADS equivalent) and 145,000...
Jun 19, 2019 08:00 am ET
Immuron to Commence US Non-Deal Institutional Investor Roadshow
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of many gut mediated pathogens, today is please to release to...
Jun 12, 2019 07:00 am ET
US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of many gut mediated pathogens, today is pleased to provide...
May 30, 2019 08:00 am ET
Immuron Announces the Closing of Public Offering of ADSs
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced the closing of its previously...
May 23, 2019 09:10 pm ET
Immuron Prices Underwritten Public Offering of ADSs
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced the pricing of an underwritten...
May 23, 2019 04:45 pm ET
Immuron Announces Proposed Public Offering of ADSs
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced that it intends to offer and...
Apr 30, 2019 02:36 pm ET
Immuron CEO Dr. Gary S. Jacob to Present at the ThinkEquity Conference on May 2, 2019
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immuno-therapeutics for the treatment of gut mediated diseases, today announced that CEO Dr. Gary S. Jacob will present...
Apr 17, 2019 09:00 am ET
Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced the appointment of Dr. Gary S....
Apr 15, 2019 09:00 am ET
Immuron sales surge by 66% in the Third Quarter of FY19
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced its third quarter FY19 sales results for...
Apr 11, 2019 10:00 am ET
Immuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immuno-therapeutics for the treatment of gut mediated diseases, today announced the issuance of a patent by the United...
Apr 11, 2019 09:00 am ET
Immuron Aims to Secure FDA Approval for IMM-124E to Prevent Travelers’ Diarrhea
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced plans to pursue clinical...
Jan 29, 2019 09:30 am ET
Travelan® FY19 1st Half Update and Geographic Expansion into North America
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced sales results for its commercially...
Jan 08, 2019 02:32 am ET
Immuron Receives $1.19M R&D Tax Concession Refund
Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of $1.19 million for...
Nov 19, 2018 09:00 am ET
Immuron Appoints Gary S. Jacob, Ph.D., Experienced US Based Biotechnology Executive, as CEO
Immuron Limited, (IMC or the Company), (ASX: IMC; NASDAQ: IMRN), is pleased to announce the appointment of Gary S. Jacob as Chief Executive Officer. Dr Jacob is the former Chairman, President and Chief Executive Officer of Synergy Pharmaceuticals...
Nov 09, 2018 06:00 am ET
NASH clinical trial presentation and continued revenue growth
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated diseases, today announced that the IMM-124E NASH...
Sep 05, 2018 10:00 am ET
US Department of Defense Reports Travelan Protects Against Shigella in Primates
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of many gut mediated pathogens, today is pleased to...
Jul 25, 2018 10:00 am ET
Immuron Reports Record Revenue Exceeding AU$2 million for the FY18 year
Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious...
Jul 24, 2018 06:30 am ET
Immuron Announces it has Received a European Patent Grant for NASH treatment
Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is an Australian microbiome biopharmaceutical Company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious...
Jul 24, 2018 06:28 am ET
US Department of Defense Research Collaboration Moves Forward
Immuron Limited (ASX:IMC) (NASDQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated pathogens, today is pleased to provide shareholders...
Jun 25, 2018 08:36 pm ET
Immuron Announces Board Appointment
Australian biopharmaceutical company Immuron Limited (ASX:IMC), is pleased to announce the appointment of New York based Mr. Richard Jay Berman to serve as a Director of the Company effective from 1 July 2018. Richard Berman's business career...
May 07, 2018 09:43 pm ET
Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program
Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious...
Apr 23, 2018 06:57 pm ET
Immuron CEO to Present at RedChip Global Online Growth Conference
MELBOURNE, Australia, April 23, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), Australian microbiome biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, is pleased to...
Mar 13, 2018 06:20 pm ET
Immuron Announces A$5.1M Private Placement to U.S. Fund
MELBOURNE, Australia, March 13, 2018 (GLOBE NEWSWIRE) --
Mar 13, 2018 09:30 am ET
Immuron Progresses Discussions with Institutional Funds
MELBOURNE, Australia, March 13, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, wishes to...
Mar 13, 2018 02:15 am ET
UPDATE -- Immuron Commences US Non-Deal Institutional Investor Roadshow
MELBOURNE, Australia, March 13, 2018 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC)(NASDQ:IMRN) is pleased to release to shareholders and investors its latest Company Presentation ahead of commencing a comprehensive roadshow to investment institutions, analysts and...
Mar 12, 2018 08:17 am ET
Immuron Commences US Non-Deal Institutional Investor Roadshow
MELBOURNE, Australia, March 12, 2018 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC)(NASDQ:IMRN) is pleased to release to shareholders and investors its latest Company Presentation ahead of commencing a comprehensive roadshow to investment institutions, analysts and...
Mar 07, 2018 06:30 pm ET
Immuron Reports Positive Results in NASH Clinical Trial
Oral IMM-124E Significantly Reduces LPS, a Major Factor in Liver Inflammation
Mar 07, 2018 05:06 pm ET
Immuron Limited Issues Correction to Misleading Halt Announcement Headline
MELBOURNE, Australia, March 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) wishes to correct a misleading halt announcement released over the wire yesterday.
Feb 16, 2018 09:30 am ET
Jan 24, 2018 09:30 am ET
Immuron to Receive $2.16M R&D Tax Concession Refund
Melbourne, Australia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company will receive a cash refund...
Jan 10, 2018 09:00 am ET
CEO to Present on US Investor TV Show and at Biotech Conference
MELBOURNE, Australia, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to advise investors that CEO Dr Jerry Kanellos, was interviewed on The RedChip Money Report US television program. The interview will air...
Dec 06, 2017 09:04 am ET
Immuron to Present at RedChip’s Global Online Growth Conference
MELBOURNE, Australia, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) wishes to advise investors that CEO Dr Jerry Kanellos is scheduled to present at RedChip’s Global Online Growth Conference on Wednesday, December 6th, 2017,...
Nov 22, 2017 09:00 am ET
Van Leeuwenhoeck Institute Updates Immuron Research Coverage
MELBOURNE, Australia, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (the “Company”) wishes to advise investors that Van Leeuwenhoeck Institute, a prominent European and US-based Life Sciences Research and Analyst firm (“VLI”), has published an updated Equity...
Nov 15, 2017 09:00 am ET
Immuron Granted US Patent for NASH Treatment
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of gut-mediated diseases, is today pleased to announced that a Notice...
Nov 09, 2017 09:00 am ET
Immuron Successfully Completes NASH Phase II Clinical Study Milestone
MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of gut-mediated diseases, announced today that it has completed its Last...
Nov 08, 2017 09:00 am ET
Jul 10, 2017 08:30 am ET
NASH Phase II Interim Analysis Reveals Improvement in Liver Enzymes (AST and ALT) with Good Safety and Tolerability
MELBOURNE, Australia, July 10, 2017 (GLOBE NEWSWIRE) -- Australian biopharmaceutical company, Immuron Limited (ASX:IMC) (NASDAQ:IMRN), is pleased to announce safety and efficacy results of the interim analysis of its ongoing IMM-124E Phase II study in NASH.  The objectives of this analysis was to establish the safety of the compound and to provide a preliminary read on efficacy signals....
Jun 08, 2017 05:43 pm ET
Immuron Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing – Raising US $6.1 Million
MELBOURNE, Australia, June 08, 2017 (GLOBE NEWSWIRE) -- Australian biopharmaceutical company Immuron Limited (ASX:IMC) (NASDAQ:IMRN), today announced the pricing of its initial public offering in the United States of 610,000 American Depository Shares ("ADSs") and warrants to purchase up to 610,000 ADSs.  Each ADS, representing 40 Ordinary Shares of the Company, and each warrant to purchase one ADS, are offered at a combined price to the public of $10.00.  The warrants will have a per ADS exercise price of $10.00, are exercisable immediately, and will have a term of five years....